6th Rare and Genetic Kidney Disease DD Summit
August 18 - 20, 2026 - MA USHanson Wade
info@hansonwade.com
Phone:+16174554188
The 6th Rare and Genetic Kidney Disease Drug Development Summit is the industry's only meeting dedicated exclusively to advancing therapies across IgAN, FSGS, ADPKD, Alport syndrome, C3G, and related renal indications. Bringing together leaders from biopharma, academia, and patient advocacy, this summit spans discovery through commercialization to support smarter, faster decision-making across kidney disease pipelines. As competition intensifies in rare and genetic kidney disease drug development, companies are under increasing pressure to differentiate assets, generate robust clinical evidence, and accelerate timelines to patients. Accelerated approval pathways have fundamentally reshaped how teams approach target evaluation, surrogate endpoint selection, and trial design within small, heterogeneous patient populations. With more programs progressing into mid- and late-stage development than ever before, the stakes for getting these decisions right have never been higher. At the same time, persistent challenges in patient recruitment, uncertainty around clinically meaningful surrogate endpoints, and incomplete mechanistic understanding continue to slow trials and increase risk. To move the field forward, teams must adopt more precise patient stratification strategies, build stronger translational models, and optimize trial designs that balance scientific rigor with operational feasibility. This year's summit convenes experts from organizations advancing approved and late-stage therapies, including Novartis, Calliditas, and Travere Therapeutics, to share real-world data, pressure-test development strategies, and benchmark approaches across the renal landscape. Attendees will gain practical insights into novel target validation, endpoint selection, and patient-focused trial design that can be applied directly to ongoing and future programs. Join the community shaping the next generation of kidney disease therapies and leave with actionable strategies to advance promising assets from discovery to patients. Time: 7:00 am to 5:00 pm